Group 1 - Topicus.com Inc. plans to release its fourth quarter results on February 26, 2025 [1] - The quarterly results will be available via press release and on the Company's website and SEDAR website after market close on the release date [1] - Topicus' subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI" [2] Group 2 - Topicus specializes in acquiring, managing, and building vertical market software businesses [2]

Group 1 - Topicus.com Inc. has announced the acquisition of 9.99% of the issued shares in Asseco Poland S.A. at a price of 85 PLN per share from Cyfrowy Polsat S.A. [1] - Topicus.com Inc.'s subsidiaries Yukon Niebieski Kapital B.V. and TSS Europe B.V. have signed a shareholders' agreement with the Adam Góral Family Foundation to govern their cooperation regarding their shareholdings in Asseco Poland S.A. [1] - The shareholders' agreement will take effect upon the completion of Yukon's acquisition of 12,318,863 treasury shares from Asseco Poland S.A., representing 14.84% of the company's share capital, also at a price of 85 PLN per share [1] Group 2 - Asseco Group operates in the information technology sector and has a presence in 62 countries, offering proprietary IT solutions across various economic sectors [3] - The Adam Góral Family Foundation, established by the CEO of Asseco Poland, operates under the Polish Family Foundation Act and is registered in Rzeszów, Poland [4] - Topicus.com Inc. is a leading provider of vertical market software in Europe, focusing on acquiring and managing software companies that provide specialized solutions for public and private sector clients [5]

Group 1 - Topicus.com Inc. announced the acquisition of 8,300,029 shares in Asseco Poland S.A. from Cyfrowy Polsat S.A., representing approximately 9.99% of the issued shares in Asseco Poland S.A. at a price of 85 PLN per share [1] - Asseco Group operates in 62 countries and is engaged in information technology, offering comprehensive IT solutions for all sectors of the economy [2] - Topicus.com Inc. is a pan-European provider of vertical market software and platforms, focusing on long-term growth potential in various European markets [3] Group 2 - Cyfrowy Polsat S.A. is a leading media and telecom group in Poland, providing digital pay-TV, telephony, broadband internet, and operating in renewable energy [4]

Core Insights - Florida Blue has launched a new oncology care model aimed at improving access to high-quality cancer care for its myBlue members, developed in collaboration with Sanitas Medical Centers and The Oncology Institute [1][4] - The program focuses on personalized, evidence-based treatment plans and emphasizes collaboration between oncologists and primary care providers to enhance patient outcomes and overall health [3][4] Company Overview - Florida Blue is the leading health insurer in Florida, serving over six million members across all 67 counties and has been in operation for more than 80 years [6] - The Oncology Institute is a prominent value-based oncology group in the U.S., providing high-quality cancer care at 14 locations in Central and South Florida [2][12] - Sanitas Medical Centers offers comprehensive primary care to nearly half a million Florida Blue members through 60 locations [2] Program Details - The new oncology care model connects myBlue members diagnosed with cancer to their own TOI oncology team, ensuring personalized treatment plans and support from primary care providers [3] - The program aims to facilitate seamless communication and coordination among healthcare providers, patients, and their families, enhancing the overall care experience [3][4] Enrollment Information - Individuals not currently enrolled in myBlue can sign up during the Marketplace open enrollment period, which ends on January 15, or at any time if they qualify for special enrollment [5]

Core Insights - Grapevine's digital supply chain solutions have enabled The Oncology Institute (TOI) to achieve over $1.7 million in medical supply savings year to date, with monthly savings reaching 61% in July 2024, highlighting the effectiveness of these innovations in healthcare [2][6]. Group 1: Cost Savings and Efficiency - The Oncology Institute's significant savings demonstrate the potential of Grapevine's digital procurement platform to eliminate inefficiencies in healthcare supply chains, ultimately reducing costs for patients [3][4]. - Grapevine's platform enhances the reliability and efficiency of healthcare supply chains by providing visibility into inventory levels, recommending alternative suppliers, and enabling seamless order tracking, which allows medical facilities to maintain high-quality care [5][6]. Group 2: Strategic Partnerships and Supplier Diversification - The partnership between Grapevine and TOI has allowed for a diversified supplier network, reducing reliance on single-source distributors and mitigating risks associated with supply shortages and inflated prices [4][7]. - By leveraging AI-driven procurement solutions, TOI has increased competition among suppliers, leading to lower costs and a more resilient supply chain [4][5]. Group 3: Industry Transformation - The success of Grapevine's platform underscores the importance of modernizing healthcare supply chains through digital transformation, promoting a future of cost-effective, resilient, and patient-centered care [6][7].

CERRITOS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2024 financial results after the market close on Wednesday, November 13, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-68 ...

CERRITOS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the nation, has joined Lantern’s leading specialty care platform. Now, Lantern members will have access to cancer care at any of The Oncology Institute’s state-of-the-art community clinics across 5 states. “At TOI, we believe that every cancer patient deserves access to the most advanced care in their community,” said Dr. Dan Virnich, Chief Executive Officer of TO ...

Group 1 - Topicus.com Inc. plans to release its third quarter results on October 31, 2024 [1] - The quarterly results will be available via press release and on the Company's website and SEDAR website after market close on the same day [1] - Topicus' subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI" [2] Group 2 - Topicus specializes in acquiring, managing, and building vertical market software businesses [2]

CERRITOS, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the nation, is proud to announce its expansion into Oregon with the opening of two new specialty cancer clinics. The clinic locations in Portland and Salem will mark TOI's first capitated partnership in the market, with plans to expand to other markets in the state as additional partnerships develop. Both initial Oregon clinic locations will offer cutting edge ca ...

Financial Data and Key Metrics Changes - Consolidated revenue for Q2 2024 was $98.6 million, an increase of 22.9% compared to Q2 2023 and a 4.1% increase compared to Q1 2024 [9] - Gross profit in Q2 2024 was $13 million, an increase of 8.8% compared to Q1 2024 [10] - Net loss for Q2 2024 was $15.5 million, an improvement of $1.4 million compared to Q2 2023 [11] - Adjusted EBITDA for Q2 2024 was negative $8.7 million [12] Business Line Data and Key Metrics Changes - Revenue growth was driven by a 76% increase in oral drug revenue [5] - The annualized revenue of new capitation deals signed year-to-date is over $41 million, with an expected adjusted EBITDA contribution of $13 million [7] Market Data and Key Metrics Changes - The company signed three new capitated contracts in Q2, covering two states and including both medical and radiation oncology services [4] - The Florida market is pacing towards strong profitability in 2025, contributing to overall TOI profitability by mid-2025 [5] Company Strategy and Development Direction - The company is undertaking a review of strategic, financial, and operational alternatives to enhance shareholder value [8] - Management remains confident in the direction of the company, emphasizing growth in value-based care delivery and pharmacy businesses [8] Management Comments on Operating Environment and Future Outlook - Management noted that the worst of the reimbursement pressures is behind them, with expectations for significant improvement in net loss and adjusted EBITDA in the second half of the year [7] - The impact of DIR fees on margins was about $2.3 million, which is expected to improve in Q3 and Q4 as the new capitation contracts go live [15] Other Important Information - The company has engaged Leerink Partners to assist with the ongoing strategic review [9] - Cash and cash equivalents as of Q2 2024 totaled $36.4 million, with an additional $9.9 million in short-term investments [12] Q&A Session Summary Question: Can you provide more details on margin pressures and improvements? - Management indicated that the DIR fee impact on margin was about $2.3 million, and they expect improvements in Q3 and Q4 due to the go-live of new capitation contracts [15] Question: How are core margins progressing excluding DIR fees? - Management confirmed that core margins are improving, with additional factors contributing to margin enhancement beyond DIR fees [16] Question: What is the outlook for cash burn and working capital? - Management clarified that the increase in accounts receivable in Q2 was primarily due to timing issues with the California Medical Rx program, which has since been resolved [17]